Zhi Tong Cai Jing·2025-09-01 01:47Core Viewpoint - Spring Medical (01858) experienced a significant stock increase of over 12%, reaching HKD 16.68 with a trading volume of HKD 21.43 million following the announcement of its mid-year results for 2025 [1] Financial Performance - The company reported a revenue of approximately CNY 488 million, representing a year-on-year growth of 28.27% [1] - The net profit attributable to shareholders was around CNY 114 million, showing a year-on-year increase of 44.85% [1] Revenue Growth Drivers - Revenue growth was primarily driven by stable supply of centralized procurement products and continuous increase in sales volume during the reporting period [1] - The company is steadily advancing its international market expansion, with export business continuing to rise [1] Profitability Improvement - The increase in net profit is attributed to stable supply of centralized procurement products, deepening international market expansion, and enhanced sales volume [1] - Internal cost reduction and efficiency improvements have strengthened the core business competitiveness, contributing to steady enhancement of profitability [1]